Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycystic Ovary Syndrome 1Motor Activity 1Insulin Resistance 1Breast Neoplasms 1Body Weight 1

Interventions

Metformin 21Letrozole 11Clomiphene 7dapagliflozin 4Contraceptives, Oral 4Chorionic Gonadotropin 4cetrorelix 3Liraglutide 3Inositol 3follitropin beta 2follitropin alfa 2drospirenone and ethinyl estradiol combination 2Musculoskeletal Manipulations 2Glycoprotein Hormones, alpha Subunit 2DLBS3233 2Cholecalciferol 2semaglutide 1saxagliptin 1lime 1follicle stimulating hormone, human, with HCG C-terminal peptide 1drospirenone 1cinnulin PF 1Urofollitropin 1Triptorelin Pamoate 1Treatment Expectations 1Thioctic Acid 1Tamoxifen 1Tablets 1Sugars 1Sperm Injections, Intracytoplasmic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Polycystic Ovary Syndrome × Resistance Training × Clear all
NCT01482286 2022-03-15

PULSE

Pennington Biomedical Research Center

Phase 3 Terminated
32 enrolled 10 charts

Body Weight, Insulin Resistance, Motor Activity, Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡